Search Results
Mar 30, 2026, 03:50 ET Masonite International Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DOOR
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
Mar 30, 2026, 03:47 ET Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
Mar 30, 2026, 03:42 ET Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT: David J. SchwartzDJS Law Group274 White Plains Road, Suite 1Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
Mar 30, 2026, 03:42 ET Plug Power Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PLUG
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
Mar 30, 2026, 03:41 ET Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
Mar 30, 2026, 03:35 ET Ramaco Resources, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - METC
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
Mar 30, 2026, 02:44 ET Paysafe Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PSFE
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
Mar 30, 2026, 02:29 ET Richtech Robotics Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RR
release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1Eastchester, NY 10709Phone: 914-206-9742Email:
More news about: DJS Law Group LLP
Mar 30, 2026, 02:23 ET EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
here.[1] Ginsberg et al. Eur Heart J. 2021;42(47):4791-4806.[2] Marston, Nicholas A et al. "Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk." The
More news about: Swedish Orphan Biovitrum AB
Mar 29, 2026, 10:00 ET Landmark ALL-RISE® Trial Results Presented at ACC.26: CathWorks FFRangio Demonstrates Similar Clinical Outcomes to Invasive Wire-based Physiology Assessment
2026 /PRNewswire/ -- Today at the American College of Cardiology's Annual Scientific Session (ACC.26) taking place in New Orleans, Louisiana, Dr. Ajay J. Kirtane from New York-Presbyterian/Columbia University Irving Medical Center, on behalf of the ALL-RISE Trial investigators, presented the one-year clinical
More news about: CathWorks
Mar 29, 2026, 10:00 ET Landmark ALL-RISE® Trial Results Presented at ACC.26: CathWorks FFRangio Demonstrates Similar Clinical Outcomes to Invasive Wire-based Physiology Assessment
2026 /PRNewswire/ -- Today at the American College of Cardiology's Annual Scientific Session (ACC.26) taking place in New Orleans, Louisiana, Dr. Ajay J. Kirtane from New York-Presbyterian/Columbia University Irving Medical Center, on behalf of the ALL-RISE Trial investigators, presented the one-year clinical
More news about: CathWorks
Mar 28, 2026, 16:45 ET REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
cardiovascular disease event risk. J Am Coll Cardiol. 2024;76(13):1507-1516.Kalra DK, Ray KK, Bajaj A, et al. Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: A meta-analysis. J Clin Lipidol. 2026.Shapiro
More news about: Amgen
Mar 28, 2026, 15:15 ET Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
2026;doi:10.1002/art.70134.5 Mease PJ, et al. Arthritis Rheum. 2005;52(10):3279-3289.6 Mease PJ, et al. N Engl J Med. 2015;373(14):1329-1339.7 Mease PJ, et al. Ann Rheum Dis. 2017;76(1):79-87.8 Deodhar A, et al.
More news about: Eli Lilly and Company
Mar 28, 2026, 14:00 ET Dual Imaging Identifies Cause of Heart Attack in Patients Without Blocked Arteries
Michael J. Attubato, MD;
More news about: NYU Langone Health
Mar 28, 2026, 10:00 ET ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
results from the Phase 3, placebo- and active comparator-controlled ICONIC-ADVANCE 1 & ICONIC ADVANCE 2 trials. 732283 Soung J. et al. Durability of icotrokinra (targeted oral peptide) effects in adolescents with moderate-to-severe plaque psoriasis: One-year results from the ICONIC-LEAD
More news about: Johnson & Johnson
Mar 27, 2026, 20:59 ET Firstrust Bank Partners with Sharing Excess to Expand Food Access for TSA Employees at Philadelphia International Airport Working Without Pay
employees."At Firstrust, our mission is to cultivate prosperity for our customers, our employees, and the communities we serve," said Richard J. Green, Executive Chairman and Owner of Firstrust Bank. "Expanding access to food for TSA employees through Sharing Excess is one way we seek to fulfill
More news about: Firstrust Bank
Mar 27, 2026, 16:54 ET Real America's Voice en Español Names Julio Gonzalez as President
network focused on delivering news and content that resonates with Spanish-speaking audiences across the country.As a former member of the Donald J. Trump for President Advisory Board and the Private Economic Council, chaired by economist Stephen Moore, Gonzalez brings extensive experience and relationships
More news about: Real America’s Voice
Mar 27, 2026, 16:15 ET BetterInvesting™ Magazine Update on NVIDIA Corp. (NASDAQ: NVDA) and Tennant Company (NYSE: TNC)
Review Committee believes is worthy of further study from an undervalued perspective. Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.Doron P. Levin, an editor of the magazine, serves as
More news about: BetterInvesting
Mar 27, 2026, 15:38 ET Wilentz, Goldman & Spitzer, P.A. Welcomes Roberto J. Benites to the Firm
N.J., March 27, 2026 /PRNewswire/ -- Wilentz, Goldman & Spitzer, P.A. is pleased to announce that Roberto J. Benites has joined the firm as Counsel in its Workers' Compensation Team in the Woodbridge office. Mr. Benites returns to Wilentz, where he began
More news about: Wilentz, Goldman & Spitzer, P.A.
Mar 27, 2026, 13:53 ET Darkroom Appoints Former IPG and dentsu Commerce Leader J. William Margaritis as SVP of Strategy
AI-native growth marketing agency behind more than $5 billion in attributable commerce revenue, has appointed J. William Margaritis as Senior Vice President of Strategy. The hire signals an accelerated push into enterprise commerce as Darkroom expands its capabilities
More news about: Darkroom Agency
Mar 27, 2026, 12:59 ET Hoag Advances Plans for Organ Transplant Center
and proximity to home matter most."This is about building a program that meets the needs of this community at the highest level," said Kenneth J. Chang, M.D., the James & Pamela Muzzy Executive Medical Director Endowed Chair in GI Cancer and Executive Director of Hoag's Digestive Health Institute.
More news about: Hoag
Mar 27, 2026, 10:00 ET Grant & Eisenhofer P.A. Announce a Summary Notice of Pendency and Proposed Settlement For All Current Stockholders of Hertz Global Holdings, Inc. ("Hertz") Stock and All Persons or Entities Who or Which Held Shares of Hertz Global Holdings, Inc. Stock Anytime Between and Including November 10, 2021 and February 9, 2023
www.HertzStockholderDerivativeSettlement.com Inquiries, other than requests for the Notice, should be made to Plaintiff's Counsel:GRANT & EISENHOFER P.A. Attn: Michael J. Barry/Vivek Upadhya 123 Justison Street Wilmington, DE 19801 (302) 622-7000
More news about: Grant & Eisenhofer P.A.
Mar 27, 2026, 10:00 ET AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
except as required by law.ReferencesTakeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017 Mar;76(3):377-390. doi: 10.1016/j.jaad.2016.07.064. PMID: 28212759;
More news about: AbbVie
Mar 27, 2026, 09:00 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. J Invest Dermatol. 2019;139(7):1480-1489. doi:10.1016/j.jid.2018.12.0187 Merola J, et al. Patients with Atopic Dermatitis with a Stable Response to Lebrikizumab Flare Less in a Long-Term
More news about: Eli Lilly and Company
Mar 27, 2026, 09:00 ET UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
2021;397(10273):487–98.4. Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus Secukinumab in Plaque Psoriasis. N Engl J Med. 2021;385(2):142–52.5. Armstrong AW, Schupp C, Wu J, et al. Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis
More news about: UCB